

Buy EUR <b>7.50</b>	
Price	EUR 5.16
Upside	<b>45.3</b> %

Value Indicators:	EUR	Warburg ESG Risk Score:	2.3	Description:	
DCF:	7.50	ESG Score (MSCI based):	3.0	Soft- and hardware for data	
FCF-Value Potential 23e:	8.20	Balance Sheet Score:	4.0	exchange for e.g. industrial	plants
		Market Liquidity Score:	0.0	and automotive electronics	
Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2021e
Market cap:	47.0	Freefloat	62.6 %	Beta:	1.3
No. of shares (m):	9.1	Trier Asset Mgmt	22.4 %	Price / Book:	0.7 x
EV:	62.5	Alois Widmann	15.0 %	Equity Ratio:	58 %
Freefloat MC:	29.4			Net Fin. Debt / EBITDA:	1.2 x
Ø Trad. Vol. (30d):	25.65 th			Net Debt / EBITDA:	1.4 x

## Softing aims for double-digit growth after strong Q4

Stated Figure	es Q4/2	2020:						
FY End: 31.12. in EUR m	Q4 20	Q4 20e	Q4 19	yoy	20	20e	19	yoy
Sales	21.9	22.3	27.0	-19 %	77.6	78.0	91.1	-15 %
EBITDA	2.9	5.8	3.2	-8 %	7.8	10.7	12.1	-36 %
Margin	13.3 %	26.1 %	11.8 %		10.0 %	13.7 %	13.3 %	
EBIT	-2.8	-2.4	1.1	n.a.	-3.9	-3.5	4.3	n.a.
Margin	-12.7 %	-10.7 %	4.3 %		-5.1 %	-4.5 %	4.7 %	
EPS	-0.26	-0.04	0.06	n.a.	-0.52	-0.30	0.31	n.a.

#### Comment on Figures:

- FY sales in line with the preliminary figures and the company target of just below EUR 80m
- Operating EBIT of EUR 1.6m above the guided range of EUR 0.0-0.5m
- The reported EBIT is burdened by a EUR 3.5m impairment effect

Softing has published its final figures for 2020, which were in line with the preliminary results, and has provided an outlook for this year. The company generated EUR 78m in sales as guided for (just below EUR 80m). The EUR 13.5m-decline in the company's top line was mainly a result of its Automotive business, which saw a sales decline of EUR 9.0m (-37%) driven by a COVID-related lull in demand and delays in the GlobalmatiX roll-out. The IT Networks segment (-27%) was impacted by the cancellation of trade fairs and also contributed to a declining top line, while the Industrial division was able to almost maintain its revenues (-4%).


The operating EBIT of EUR 1.6m, was significantly higher than the target range of EUR 0.0-0.5m, after a strong Q4. The reported EBIT of -3.9m was however significantly lower than its 2019 value of EUR 4.3m, mainly as a consequence of the weaker Automotive business and an impairment effect of EUR 3.5m for diagnostic tools for combustion engines.

For 2021, under the condition of an improvement in the pandemic environment, Softing is targeting a growth rate of 10-15% and an EBIT of EUR 1.5-3.0m. The growth should be driven by the continuation of the GlobalmatiX roll-out, postponed in 2020, with 10,000 new installations in the current year. Since the associated margin profile is lower in the year of installation and higher as the installed hardware generates service revenues, we adjusted our EBIT estimate for the 2021. With our updated model, we confirm our target price and our Buy recommendation for Softing.

Changes in E	Estimates:					
FY End: 31.12. in EUR m	2021e (old)	+/-	2022e (old)	+/-	2023e (old)	+/-
Sales	87.0	0.0 %	100.0	0.0 %	n.a.	n.m.
EBITDA	12.6	-11.3 %	14.1	0.0 %	n.a.	n.m.
EBIT	4.2	-33.7 %	5.4	0.0 %	n.a.	n.m.
EPS	0.30	-36.7 %	0.39	0.0 %	n.a.	n.m.

### Comment on Changes:

2021 EBIT estimate adjusted to the upper end of guidance




Rel. Performance vs CDAX:	
1 month:	-12.2 %
6 months:	-12.8 %
Year to date:	-8.3 %
Trailing 12 months:	-50.0 %

Company events:	
04.05.21	Q1
05.05.21	AGM
13.08.21	Q2
15.11.21	Q3

FY End: 31.12. in EUR m	CAGR (20-23e)	2017	2018	2019	2020	2021e	2022e	2023e
Sales	12.1 %	78.7	83.9	91.1	77.6	87.0	100.0	109.2
Change Sales yoy		-2.1 %	6.6 %	8.6 %	-14.8 %	12.1 %	14.9 %	9.2 %
Gross profit margin		64.9 %	61.8 %	62.9 %	59.5 %	61.2 %	61.0 %	60.6 %
EBITDA	25.0 %	6.8	9.0	12.1	7.8	11.2	14.1	15.1
Margin		8.7 %	10.7 %	13.3 %	10.0 %	12.9 %	14.1 %	13.9 %
EBIT	-	2.3	4.1	4.3	-3.9	2.8	5.4	6.2
Margin		3.0 %	4.9 %	4.7 %	-5.1 %	3.2 %	5.4 %	5.7 %
EBIT adj.	68.4 %	1.1	3.5	3.9	1.6	4.3	6.6	7.4
Net income	-	0.7	3.3	2.8	-4.7	1.8	3.5	4.1
EPS	-	0.10	0.38	0.31	-0.52	0.19	0.39	0.45
DPS	7.7 %	0.13	0.13	0.04	0.04	0.04	0.05	0.05
Dividend Yield		1.2 %	1.5 %	0.5 %	0.7 %	0.8 %	1.0 %	1.0 %
FCFPS		-0.27	0.19	0.04	-0.38	0.42	0.12	0.29
FCF / Market cap		-2.4 %	2.3 %	0.5 %	-6.5 %	8.1 %	2.4 %	5.6 %
EV / Sales		1.1 x	1.0 x	0.8 x	0.9 x	0.7 x	0.6 x	0.6 x
EV / EBITDA		12.7 x	8.9 x	6.3 x	9.0 x	5.6 x	4.5 x	4.2 x
EV / EBIT adj.		77.7 x	22.8 x	19.4 x	44.8 x	14.5 x	9.7 x	8.5 x
EV / EBIT		37.0 x	19.7 x	17.6 x	n.a.	22.3 x	11.8 x	10.3 x
P/E		112.0 x	22.6 x	24.8 x	n.a.	27.2 x	13.2 x	11.5 x
FCF Potential Yield		2.6 %	2.4 %	5.9 %	4.8 %	6.2 %	9.4 %	10.7 %
Net Debt		4.5	5.2	6.0	17.5	15.5	16.7	16.5
ROCE (NOPAT)		2.7 %	4.5 %	4.0 %	n.a.	2.5 %	4.5 %	4.6 %
Guidance:	Sales growth 1	10%-15%, EE	BIT EUR 1.5-	3.0m				

Analyst






## **Company Background**

- Softing has the necessary expertise on information exchange between various devices, sensors, plant and software solutions in automated processes. Its business activity comprises three segments.
- Industrial Automation: hardware and software solutions for the exchange of information in all kinds of production including assembly lines, chemical plants, oil and gas extraction or refineries.
- IT Networks: diagnostic devices which are used in industrial automation and for the diagnosis of copper and optical fibre networks in data centers and office installations
- Automotive Electronics: The solutions allow engineers and workshop mechanics to test automotive electronics in the development phase, production or repair and to recognise errors via data evaluation.
- The solutions in the automotive segment are not for application within the vehicles and therefore do not pose a product re-call risk for the company.

## **Competitive Quality**

- European market leader in the networking of various production plant elements as well as in business-related software (so-called OPC products).
- World market leader in components for the exchange of information in gas and oil plants. Some >50% of all devices registered worldwide that are used in these plants include components from Softing.
- Softing's participation in international committees that set standards for the exchange of information. This contributes to a short time-to-market.
- The high complexity of Softing's business activity is the single most important barrier to market entry for potential competitors.



Source: Company



DCF model														
	Detailed	d forecas	t period				7	ransition	al period					Term. Value
Figures in EUR m	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	
Sales	87.0	100.0	109.2	114.7	120.1	125.5	130.9	136.2	141.5	146.7	151.8	156.9	160.0	
Sales change	12.1 %	14.9 %	9.2 %	5.0 %	4.8 %	4.5 %	4.3 %	4.1 %	3.9 %	3.7 %	3.5 %	3.3 %	2.0 %	2.0 %
EBIT	2.8	5.4	6.2	6.9	7.2	7.5	7.9	8.2	8.5	8.8	9.1	9.4	9.6	
EBIT-margin	3.2 %	5.4 %	5.7 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	
Tax rate (EBT)	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	
NOPAT	2.0	3.8	4.3	4.8	5.0	5.3	5.5	5.7	5.9	6.2	6.4	6.6	6.7	
Depreciation	8.4	8.7	9.0	7.9	8.3	8.7	9.0	9.4	9.8	10.1	10.5	10.8	11.0	
in % of Sales	9.7 %	8.7 %	8.2 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	
Changes in provisions	-0.6	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	
Change in Liquidity from														
- Working Capital	-2.5	2.7	2.0	1.4	1.1	1.1	1.1	1.1	1.1	1.0	1.0	1.0	0.6	
- Capex	6.8	6.8	6.8	8.0	8.4	8.8	9.2	9.5	9.9	10.3	10.6	11.0	11.2	
Capex in % of Sales	7.8 %	6.8 %	6.2 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	5.5	3.0	4.5	3.3	4.0	4.2	4.4	4.6	4.9	5.1	5.3	5.5	6.0	7
PV of FCF	5.3	2.7	3.7	2.5	2.8	2.8	2.8	2.7	2.6	2.6	2.5	2.4	2.4	49
share of PVs		13.36 %						29.98	3 %					56.66 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2033e	38		
				Terminal Value	49		
Debt ratio	20.00 %	Financial Strength	1.40	Financial liabilities	25		
Cost of debt (after tax)	2.1 %	Liquidity (share)	1.30	Pension liabilities	3		
Market return	7.00 %	Cyclicality	1.30	Hybrid capital	0		
Risk free rate	1.50 %	Transparency	1.30	Minority interest	0		
		Others	1.30	Market val. of investments	0		
				Liquidity	9	No. of shares (m)	9.1
WACC	7.43 %	Beta	1.32	Equity Value	68	Value per share (EUR)	7.49

06113	itivity ve	ilue per on	are (LUIX	,													
		Terminal (	Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.55	8.4 %	5.48	5.62	5.76	5.91	6.08	6.26	6.45	1.55	8.4 %	3.71	4.45	5.18	5.91	6.65	7.38	8.11
1.43	7.9 %	6.10	6.27	6.44	6.63	6.84	7.07	7.32	1.43	7.9 %	4.24	5.04	5.84	6.63	7.43	8.23	9.02
1.38	7.7 %	6.45	6.63	6.83	7.04	7.28	7.53	7.81	1.38	7.7 %	4.54	5.38	6.21	7.04	7.88	8.71	9.54
1.32	7.4 %	6.83	7.03	7.25	7.49	7.75	8.04	8.37	1.32	7.4 %	4.87	5.75	6.62	7.49	8.36	9.24	10.11
1.26	7.2 %	7.24	7.46	7.71	7.98	8.28	8.61	8.98	1.26	7.2 %	5.23	6.15	7.07	7.98	8.90	9.81	10.73
1.21	6.9 %	7.68	7.94	8.22	8.53	8.87	9.25	9.67	1.21	6.9 %	5.63	6.60	7.56	8.53	9.49	10.45	11.42
1.09	6.4 %	8.71	9.04	9.40	9.80	10.25	10.76	11.33	1.09	6.4 %	6.57	7.65	8.72	9.80	10.88	11.95	13.03

<sup>•</sup> The cyclical components of the business activity and the low liquidity of the share raise capital costs.



### Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Net Income before minorities	0.7	3.3	2.9	-4.6	1.8	3.5	4.1
+ Depreciation + Amortisation	4.5	4.9	7.8	11.7	8.4	8.7	9.0
- Net Interest Income	-1.2	0.5	-0.1	-1.5	-0.3	-0.4	-0.4
- Maintenance Capex	4.2	5.8	6.4	5.2	5.1	5.1	5.1
+ Other	0.0	0.0	0.0	0.0	-1.5	-1.5	-1.5
= Free Cash Flow Potential	2.3	1.9	4.4	3.4	3.9	6.0	6.8
FCF Potential Yield (on market EV)	2.6 %	2.4 %	5.9 %	4.8 %	6.2 %	9.4 %	10.7 %
WACC	7.43 %	7.43 %	7.43 %	7.43 %	7.43 %	7.43 %	7.43 %
= Enterprise Value (EV)	86.7	80.5	75.9	69.9	62.5	63.7	63.5
= Fair Enterprise Value	30.4	26.2	59.8	45.4	51.9	80.6	91.4
- Net Debt (Cash)	14.4	14.4	14.4	14.4	13.0	14.2	14.0
- Pension Liabilities	3.1	3.1	3.1	3.1	2.5	2.5	2.5
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<ul> <li>Market value of minorities</li> </ul>	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	12.9	8.8	42.4	27.9	36.4	63.9	74.9
Number of shares, average	7.3	8.8	9.1	9.1	9.1	9.1	9.1
= Fair value per share (EUR)	1.76	1.00	4.65	3.07	4.01	7.03	8.25
premium (-) / discount (+) in %					-22.4 %	36.3 %	59.8 %
Sensitivity Fair value per Share (EUR)							
10.43	% 0.46	0.13	2.76	1.63	2.36	4.47	5.34
9.43	% 0.71	0.35	3.26	2.01	2.79	5.14	6.10
8.43	% 1.02	0.62	3.87	2.47	3.32	5.96	7.03
WACC 7.43		0.96	4.65	3.06	3.99	7.01	8.23
6.43		1.41	5.68	3.84	4.88	8.39	9.79
5.43		2.02	7.07	4.90	6.09	10.27	11.92
4.43	% 3.68	2.91	9.11	6.44	7.85	13.01	15.03

<sup>·</sup> Capitalised own work is a significant element of the capex.

<sup>•</sup> FCF-Value-CAGR 2017-2023e: 34%

# Softing



Valuation							
	2017	2018	2019	2020	2021e	2022e	2023e
Price / Book	1.6 x	1.1 x	1.0 x	0.8 x	0.7 x	0.7 x	0.6 x
Book value per share ex intangibles	1.37	0.92	0.76	0.63	0.75	1.70	2.71
EV / Sales	1.1 x	1.0 x	0.8 x	0.9 x	0.7 x	0.6 x	0.6 x
EV / EBITDA	12.7 x	8.9 x	6.3 x	9.0 x	5.6 x	4.5 x	4.2 x
EV / EBIT	37.0 x	19.7 x	17.6 x	n.a.	22.3 x	11.8 x	10.3 x
EV / EBIT adj.*	77.7 x	22.8 x	19.4 x	44.8 x	14.5 x	9.7 x	8.5 x
P/FCF	n.a.	44.1 x	213.1 x	n.a.	12.4 x	41.3 x	17.7 x
P/E	112.0 x	22.6 x	24.8 x	n.a.	27.2 x	13.2 x	11.5 x
P / E adj.*	112.0 x	22.6 x	24.8 x	n.a.	27.2 x	13.2 x	11.5 x
Dividend Yield	1.2 %	1.5 %	0.5 %	0.7 %	0.8 %	1.0 %	1.0 %
FCF Potential Yield (on market EV)	2.6 %	2.4 %	5.9 %	4.8 %	6.2 %	9.4 %	10.7 %
*Adjustments made for: -							


Company Specific Items							
	2017	2018	2019	2020	2021e	2022e	2023e
order entries	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
book-to-bill	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
order book	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.



Consolidated profit & loss							
In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Sales	78.7	83.9	91.1	77.6	87.0	100.0	109.2
Change Sales yoy	-2.1 %	6.6 %	8.6 %	-14.8 %	12.1 %	14.9 %	9.2 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	4.6	4.4	5.5	3.7	3.7	4.0	3.9
Total Sales	83.3	88.3	96.6	81.3	90.7	104.0	113.1
Material expenses	32.2	36.5	39.3	35.1	37.5	43.0	47.0
Gross profit	51.1	51.8	57.3	46.1	53.2	61.0	66.1
Gross profit margin	64.9 %	61.8 %	62.9 %	59.5 %	61.2 %	61.0 %	60.6 %
Personnel expenses	33.0	33.4	35.4	31.7	34.6	36.6	40.1
Other operating income	0.9	1.4	8.0	1.7	1.4	1.0	1.0
Other operating expenses	12.1	10.8	10.5	8.4	8.8	11.3	11.9
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	6.8	9.0	12.1	7.8	11.2	14.1	15.1
Margin	8.7 %	10.7 %	13.3 %	10.0 %	12.9 %	14.1 %	13.9 %
Depreciation of fixed assets	0.8	0.7	2.6	2.2	2.8	3.0	3.2
EBITA	6.1	8.3	9.5	5.6	8.4	11.1	11.9
Amortisation of intangible assets	3.7	4.2	5.2	9.5	5.6	5.7	5.8
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	2.3	4.1	4.3	-3.9	2.8	5.4	6.2
Margin	3.0 %	4.9 %	4.7 %	-5.1 %	3.2 %	5.4 %	5.7 %
EBIT adj.	1.1	3.5	3.9	1.6	4.3	6.6	7.4
Interest income	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Interest expenses	1.3	-0.5	0.3	0.3	0.2	0.2	0.2
Other financial income (loss)	0.0	0.0	0.3	-1.2	0.0	0.0	0.0
EBT	1.1	4.6	4.2	-5.4	2.5	5.1	5.8
Margin	1.4 %	5.5 %	4.7 %	-7.0 %	2.9 %	5.1 %	5.4 %
Total taxes	0.4	1.3	1.3	-0.8	0.8	1.5	1.8
Net income from continuing operations	0.7	3.3	2.9	-4.6	1.8	3.5	4.1
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	0.7	3.3	2.9	-4.6	1.8	3.5	4.1
Minority interest	0.0	0.0	0.1	0.2	0.0	0.0	0.0
Net income	0.7	3.3	2.8	-4.7	1.8	3.5	4.1
Margin	0.9 %	4.0 %	3.1 %	-6.1 %	2.0 %	3.5 %	3.7 %
Number of shares, average	7.3	8.8	9.1	9.1	9.1	9.1	9.1
EPS	0.10	0.38	0.31	-0.52	0.19	0.39	0.45
EPS adj.	0.10	0.38	0.31	-0.52	0.19	0.39	0.45
*Adjustments made for:							

Guidance: Sales growth 10%-15%, EBIT EUR 1.5-3.0m

Financial Ratios							
	2017	2018	2019	2020	2021e	2022e	2023e
Total Operating Costs / Sales	97.2 %	94.5 %	92.8 %	94.7 %	91.4 %	89.9 %	89.7 %
Operating Leverage	31.5 x	11.2 x	0.6 x	n.a.	n.a.	6.2 x	1.6 x
EBITDA / Interest expenses	5.4 x	n.m.	44.4 x	29.8 x	56.0 x	70.5 x	75.7 x
Tax rate (EBT)	35.8 %	27.7 %	31.0 %	15.5 %	30.0 %	30.0 %	30.0 %
Dividend Payout Ratio	131.5 %	34.2 %	12.4 %	n.m.	20.7 %	12.8 %	11.1 %
Sales per Employee	189,658	207,649	225,416	189,261	209,639	238,095	256,941




Source: Warburg Research Source: Warburg Research

Source: Warburg Research



Consolidated balance sheet							
In EUR m	2017	2018	2019	2020	2021e	2022e	2023
Assets							
Goodwill and other intangible assets	41.8	59.9	62.4	56.8	56.8	56.7	56.6
thereof other intangible assets	14.7	26.5	34.7	29.2	27.8	26.7	25.4
thereof Goodwill	14.5	18.0	18.1	17.5	17.5	17.5	17.5
Property, plant and equipment	2.0	2.3	5.9	5.5	12.9	20.1	27.1
Financial assets	0.0	0.0	1.5	1.5	1.5	1.5	1.5
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	43.8	62.2	69.9	63.8	71.2	78.3	85.2
Inventories	9.1	10.6	12.6	13.7	12.1	13.9	15.2
Accounts receivable	12.8	13.7	15.4	14.3	14.1	16.2	17.7
Liquid assets	10.3	9.7	14.9	10.2	9.3	10.1	10.3
Other short-term assets	4.7	3.7	4.0	3.2	3.2	3.2	3.2
Current assets	36.9	37.6	46.9	41.4	38.7	43.4	46.4
Total Assets	80.7	99.8	116.8	105.2	110.0	121.7	131.6
Liabilities and shareholders' equity							
Subscribed capital	7.7	9.1	9.1	9.1	9.1	9.1	9.1
Capital reserve	19.2	31.1	31.1	31.1	31.1	31.1	31.1
Retained earnings	25.4	28.0	29.1	22.9	24.6	28.1	32.2
Other equity components	0.0	0.0	0.0	-0.5	-1.1	3.9	8.8
Shareholders' equity	52.3	68.3	69.3	62.6	63.7	72.2	81.3
Minority interest	0.0	0.1	0.3	0.4	0.4	0.4	0.4
Total equity	52.3	68.4	69.6	63.0	64.1	72.7	81.7
Provisions	2.9	3.7	4.4	3.2	5.4	5.4	5.4
thereof provisions for pensions and similar obligations	2.2	2.1	3.1	3.1	2.5	2.5	2.5
Financial liabilities (total)	12.6	12.8	17.8	24.6	22.3	24.3	24.3
thereof short-term financial liabilities	8.4	10.7	1.6	4.7	4.7	4.7	4.7
Accounts payable	5.5	6.1	6.5	6.0	6.7	7.9	8.7
Other liabilities	7.4	8.8	18.4	8.4	11.4	11.4	11.4
Liabilities	28.4	31.4	47.2	42.2	45.9	49.1	49.9
Total liabilities and shareholders' equity	80.7	99.8	116.8	105.2	110.0	121.7	131.6


Financial Ratios							
	2017	2018	2019	2020	2021e	2022e	2023e
Efficiency of Capital Employment							
Operating Assets Turnover	4.3 x	4.1 x	3.7 x	3.1 x	2.9 x	2.5 x	2.2 x
Capital Employed Turnover	1.4 x	1.1 x	1.2 x	1.0 x	1.1 x	1.1 x	1.1 x
ROA	1.6 %	5.3 %	4.0 %	-7.4 %	2.5 %	4.5 %	4.8 %
Return on Capital							
ROCE (NOPAT)	2.7 %	4.5 %	4.0 %	n.a.	2.5 %	4.5 %	4.6 %
ROE	1.4 %	5.5 %	4.1 %	-7.2 %	2.8 %	5.2 %	5.3 %
Adj. ROE	1.4 %	5.5 %	4.1 %	-7.2 %	2.8 %	5.2 %	5.3 %
Balance sheet quality							
Net Debt	4.5	5.2	6.0	17.5	15.5	16.7	16.5
Net Financial Debt	2.3	3.1	2.9	14.4	13.0	14.2	14.0
Net Gearing	8.6 %	7.6 %	8.6 %	27.7 %	24.2 %	23.0 %	20.2 %
Net Fin. Debt / EBITDA	33.5 %	34.2 %	24.2 %	185.7 %	115.9 %	100.8 %	92.6 %
Book Value / Share	6.8	7.5	7.6	6.9	7.0	7.9	8.9
Book value per share ex intangibles	1.4	0.9	0.8	0.6	0.8	1.7	2.7





Consolidated cash flow statement							
In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Net income	0.7	3.3	2.9	-4.6	1.8	3.5	4.1
Depreciation of fixed assets	0.8	0.7	2.6	2.2	2.8	3.0	3.2
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	3.7	4.2	5.2	9.5	5.6	5.7	5.8
Increase/decrease in long-term provisions	0.0	0.0	0.0	0.0	-0.6	0.0	0.0
Other non-cash income and expenses	-0.3	0.3	1.5	-1.8	0.0	0.0	0.0
Cash Flow before NWC change	4.9	8.5	12.2	5.3	9.6	12.2	13.0
Increase / decrease in inventory	0.1	-1.5	-2.0	-1.1	1.6	-1.8	-1.3
Increase / decrease in accounts receivable	-0.2	-1.4	-1.7	1.2	0.2	<b>-2</b> .1	-1.5
Increase / decrease in accounts payable	-0.3	1.4	0.0	-0.5	0.7	1.2	0.8
Increase / decrease in other working capital positions	-1.0	2.4	1.8	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-1.3	0.9	-1.9	-0.4	2.5	-2.7	-2.0
Net cash provided by operating activities [1]	3.6	9.4	10.4	4.9	12.1	9.5	11.0
Investments in intangible assets	-4.6	-6.4	-7.4	-5.4	-5.6	-5.6	-5.6
Investments in property, plant and equipment	-1.0	-1.4	-1.1	-1.5	-1.2	-1.2	-1.2
Payments for acquisitions	-4.2	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	-1.5	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-9.8	-7.7	-8.5	-8.5	-6.8	-6.8	-6.8
Change in financial liabilities	-0.3	-1.0	6.5	1.1	-2.3	2.0	0.0
Dividends paid	-1.4	-1.0	-1.2	-0.4	-0.4	-0.4	-0.5
Purchase of own shares	0.0	0.0	0.0	-0.5	0.0	0.0	0.0
Capital measures	7.9	0.0	0.0	0.0	0.0	0.0	0.0
Other	-0.1	-0.2	-0.3	0.0	-2.0	-2.0	-2.0
Net cash provided by financing activities [3]	6.0	-2.2	3.4	-1.1	-6.1	-2.0	-4.1
Change in liquid funds [1]+[2]+[3]	-0.2	-0.5	5.3	-4.7	-0.8	0.8	0.2
Effects of exchange-rate changes on cash	-0.4	-0.1	0.0	-0.1	0.0	0.0	0.0
Cash and cash equivalent at end of period	10.3	9.7	14.9	10.2	9.3	10.1	10.3

Financial Ratios							
	2017	2018	2019	2020	2021e	2022e	2023e
Cash Flow							
FCF	-2.0	1.7	0.3	-3.4	3.8	1.1	2.6
Free Cash Flow / Sales	-2.6 %	2.0 %	0.4 %	-4.4 %	4.4 %	1.1 %	2.4 %
Free Cash Flow Potential	2.3	1.9	4.4	3.4	3.9	6.0	6.8
Free Cash Flow / Net Profit	-283.5 %	51.4 %	11.7 %	72.2 %	216.0 %	32.1 %	64.6 %
Interest Received / Avg. Cash	0.4 %	0.7 %	0.5 %	0.4 %	1.0 %	1.0 %	1.0 %
Interest Paid / Avg. Debt	8.6 %	-3.6 %	1.8 %	1.2 %	0.9 %	0.9 %	0.8 %
Management of Funds							
Investment ratio	7.1 %	9.2 %	9.3 %	9.0 %	7.8 %	6.8 %	6.2 %
Maint. Capex / Sales	5.3 %	6.9 %	7.0 %	6.7 %	5.9 %	5.1 %	4.7 %
Capex / Dep	123.9 %	156.4 %	108.5 %	59.6 %	81.0 %	78.2 %	76.0 %
Avg. Working Capital / Sales	20.5 %	20.6 %	20.3 %	24.6 %	20.7 %	18.1 %	18.8 %
Trade Debtors / Trade Creditors	232.1 %	224.8 %	237.5 %	238.7 %	210.4 %	205.1 %	203.4 %
Inventory Turnover	3.6 x	3.5 x	3.1 x	2.6 x	3.1 x	3.1 x	3.1 x
Receivables collection period (days)	59	60	62	67	59	59	59
Payables payment period (days)	63	61	60	62	65	67	68
Cash conversion cycle (Days)	100	104	94	119	85	87	89



Source: Warburg Research Source: Warburg Research Source: Warburg Research



#### **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).



#### SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or**investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Softing	3, 5	http://www.mmwarburg.com/disclaimer/disclaimer en/DE0005178008.htm



## **INVESTMENT RECOMMENDATION**

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYS	ED RESEARCH UNIVERSE BY RATING
--------------------------------	--------------------------------

Rating	Number of stocks	% of Universe
Buy	135	65
Hold	61	29
Sell	6	3
Rating suspended	5	2
Total	207	100

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	38	78
Hold	8	16
Sell	0	0
Rating suspended	3	6
Total	49	100

### PRICE AND RATING HISTORY SOFTING AS OF 29.03.2021



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Michael Heider	+49 40 309537-280	Philipp Kaiser	+49 40 309537-260
Head of Research  Henner Rüschmeier	mheider@warburg-research.com +49 40 309537-270	Real Estate Thilo Kleibauer	pkaiser@warburg-research.com +49 40 309537-257
Head of Research	hrueschmeier@warburg-research.com	Retail, Consumer Goods	tkleibauer@warburg-research.com
Stefan Augustin Cap. Goods, Engineering	+49 40 309537-168 saugustin@warburg-research.com	Eggert Kuls Engineering	+49 40 309537-256 ekuls@warburg-research.com
Jan Bauer	+49 40 309537-155	Andreas Pläsier	+49 40 309537-246
Renewables	jbauer@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Jonas Blum Telco, Media, Construction	+49 40 309537-240 jblum@warburg-research.com	Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Christian Cohrs	+49 40 309537-175	Oliver Schwarz	+49 40 309537-250
Industrials & Transportation	ccohrs@warburg-research.com	Chemicals, Agriculture	oschwarz@warburg-research.com
<b>Dr. Christian Ehmann</b> BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Simon Stippig Real Estate	+49 40 309537-265 sstippig@warburg-research.com
Felix Ellmann	+49 40 309537-120	Cansu Tatar	+49 40 309537-248
Software, IT  Jörg Philipp Frey	fellmann@warburg-research.com +49 40 309537-258	Cap. Goods, Engineering  Marc-René Tonn	ctatar@warburg-research.com +49 40 309537-259
Retail, Consumer Goods	jfrey@warburg-research.com	Automobiles, Car Suppliers	mtonn@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com	Robert-Jan van der Horst Technology	+49 40 309537-290 rvanderhorst@warburg-research.com
Mustafa Hidir	+49 40 309537-230	Andreas Wolf	+49 40 309537-140
Automobiles, Car Suppliers	mhidir@warburg-research.com	Software, IT	awolf@warburg-research.com
Ulrich Huwald Health Care, Pharma	+49 40 309537-255 uhuwald@warburg-research.com		
INSTITUTIONAL EQU			
Marc Niemann	+49 40 3282-2660	Maximilian Martin	+49 69 5050-7413
Head of Equity Sales, Germany	mniemann@mmwarburg.com	Austria, Poland	mmartin@mmwarburg.com
Klaus Schilling Head of Equity Sales, Germany	+49 40 3282-2664 kschilling@mmwarburg.com	Christopher Seedorf Switzerland	+49 69 5050-7414 cseedorf@mmwarburg.com
Tim Beckmann	+49 40 3282-2665		g
United Kingdom  Lea Bogdanova	tbeckmann@mmwarburg.com +49 69 5050-7411		
United Kingdom, Ireland	lbogdanova@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415		
Scandinavia, Austria  Alexander Eschweiler	jbuchmueller@mmwarburg.com +49 40 3282-2669	Sophie Hauer	+49 69 5050-7417
Germany, Luxembourg	aeschweiler@mmwarburg.com	Roadshow/Marketing	shauer@mmwarburg.com
Matthias Fritsch	+49 40 3282-2696	Juliane Niemann	+49 40 3282-2694
United Kingdom	mfritsch@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING			
Oliver Merckel Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com	Marcel Magiera Sales Trading	+49 40 3282-2662 mmagiera@mmwarburg.com
Elyaz Dust	+49 40 3282-2702	Bastian Quast	+49 40 3282-2701
Sales Trading	edust@mmwarburg.com	Sales Trading	bquast@mmwarburg.com
Michael Ilgenstein Sales Trading	+49 40 3282-2700 milgenstein@mmwarburg.com	Jörg Treptow Sales Trading	+49 40 3282-2658 jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude	+49 40 3282-2572	Dr. Christian Jasperneite	+49 40 3282-2439
Macro Research	cklude@mmwarburg.com	Investment Strategy	cjasperneite@mmwarburg.com
Our research can be f	found under:		
Warburg Research	research.mmwarburg.com/en/index.html	Thomson Reuters	www.thomsonreuters.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta		Monatin Month in	. 10 10 2000 2700
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com
	account of the second of the s		3@